These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
333 related items for PubMed ID: 9146664
1. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. Jackson MW, Bentel JM, Tilley WD. J Urol; 1997 Jun; 157(6):2323-8. PubMed ID: 9146664 [Abstract] [Full Text] [Related]
3. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. J Urol; 1997 Jun; 157(6):2329-33. PubMed ID: 9146665 [Abstract] [Full Text] [Related]
4. Distribution of vascular endothelial growth factor (VEGF) in prostate disease. Walsh K, Sriprasad S, Hopster D, Codd J, Mulvin D. Prostate Cancer Prostatic Dis; 2002 Jun; 5(2):119-22. PubMed ID: 12497000 [Abstract] [Full Text] [Related]
8. Angiogenically active vascular endothelial growth factor is over-expressed in malignant human and rat prostate carcinoma cells. Chen HJ, Treweeke AT, Ke YQ, West DC, Toh CH. Br J Cancer; 2000 May; 82(10):1694-701. PubMed ID: 10817506 [Abstract] [Full Text] [Related]
9. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, Tilley WD. Cancer Res; 2002 Feb 01; 62(3):854-9. PubMed ID: 11830543 [Abstract] [Full Text] [Related]
10. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Borre M, Nerstrøm B, Overgaard J. Clin Cancer Res; 2000 May 01; 6(5):1882-90. PubMed ID: 10815911 [Abstract] [Full Text] [Related]
11. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Zeng Y, Opeskin K, Baldwin ME, Horvath LG, Achen MG, Stacker SA, Sutherland RL, Williams ED. Clin Cancer Res; 2004 Aug 01; 10(15):5137-44. PubMed ID: 15297417 [Abstract] [Full Text] [Related]
16. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Kaushal V, Mukunyadzi P, Dennis RA, Siegel ER, Johnson DE, Kohli M. Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):584-93. PubMed ID: 15701844 [Abstract] [Full Text] [Related]
17. [Expression of VEGF in prostate cancer and its correlation with ET-1]. Zhou WQ, Yin HL, Zhang ZY, Yi XM, Ge JP, Zhou SG, Cheng W, Wei W, Ma HQ, Ma HH, Gao JP. Zhonghua Nan Ke Xue; 2008 Nov 15; 14(11):987-92. PubMed ID: 19102498 [Abstract] [Full Text] [Related]
20. [Expressions of telomerase reverse transcriptase and vascular endothelial growth factor and their correlation in prostate cancer]. Li X, Wang N, Zhang Y, Zhang SX, Lin Q, Tang J. Zhonghua Nan Ke Xue; 2005 Oct 15; 11(10):724-6, 730. PubMed ID: 16281501 [Abstract] [Full Text] [Related] Page: [Next] [New Search]